Portage, Michigan, July 01, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that it will report financial results for first quarter of fiscal year 2024 on Tuesday, July 30, 2024. A press release will be issued at approximately 4:05pm ET and available at Stryker - Press Releases that day. The press release will include summary financial information for the company’s second quarter of fiscal year 2024, that ended June 30, 2024.
Stryker will host a webcast at 4:30pm ET on Tuesday, July 30, to discuss results for its second quarter fiscal year 2024. The webcast can be accessed at Stryker - Events & Presentations. An archive of the webcast will also be available on the company's website two hours after the live call ends.
About Stryker
Stryker is a global leader in medical technologies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in MedSurg, Neurotechnology, Orthopaedics and Spine that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryker impacts more than 150 million patients annually. More information is available at www.stryker.com.
Contacts
For investor inquiries please contact:
Jason Beach, Vice President, Finance and Investor Relations at 269-385-2600 or This email address is being protected from spambots. You need JavaScript enabled to view it.
For media inquiries please contact:
Yin Becker, Vice President, Chief Corporate Affairs Officer at 269-385-2600 or This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$380.86 |
Daily Change: | -1.78 -0.47 |
Daily Volume: | 809,514 |
Market Cap: | US$145.190B |
May 01, 2025 March 04, 2025 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load